؉ cells fail to process KF11. This unexpected finding demonstrates that immunodominance patterns can be influenced by intracellular events independent of HLA binding motifs.
I
ntracellular processing events critically influence the epitopes presented by HLA class I molecules on the surfaces of virusinfected cells to specific CD8 ϩ T cells (21) . HIV-specific CD8 ϩ T-cell responses and their HLA restriction element together have a substantial impact on HIV disease progression (4, 5, 7, 18, 22) . Recent analyses of three closely related HLA molecules, HLA-B*57:02, HLA-B*57:03, and HLA-B*58:01, suggested that the nature of responses to four immunodominant p24-Gag epitopes has a significant impact on viral load set point (13) . Response to the KF11 (KAFSPEVIPMF) Gag epitope (6) is associated with improved HIV immune control (10) and was observed in HLA-B*57: 03-but not in HLA-B*58:01-positive individuals, despite these HLA-B alleles' having apparently similar peptide binding motifs (13, 17, 19) . Virus sequencing data show that this is not due to selection of viral escape in HLA-B*58:01-positive individuals (1, 13) . To better understand the basis for this difference, we examined the presentation of KF11 by HLA-B*57:03 and the closely related HLA-B*57:01 and HLA-B*58:01 molecules. In this study, we identified an unexpected effect of the HLA molecule on intracellular processing of viral epitopes, overriding the capacity of that HLA molecule to bind and present particular peptides that is ultimately important for HIV immune control. KF11 Gag is presented by HLA-B*57:01 and B*57:03, not by HLA-B*58:01. We showed previously that KF11 Gag is dominantly targeted by HLA-B*57:03 in a large C-clade-infected cohort, with strong selection of A163X and S165X escape mutations (1, 3, 13) . To further examine presentation of this epitope by closely related HLA-B molecules, we extended this analysis to include HLA-B*57:01, the HLA-B*57 allele most frequently expressed in Caucasians with B-clade infection together with HLA-B*58:01, expressed in 12% of C-clade-infected individuals (13, 16) . HLA-B*57:01 differs from HLA-B*57:03 at only two HLA residues (residues 114 and 116) and from HLA-B*58:01 at three residues (HLA residues 45, 46, and 97) involved in forming the B and F pockets, respectively (Table 1) .
Strong cytotoxic-T-lymphocyte (CTL) responses by HLA-B*58:01-positive individuals are made only to the HIV p24-Gag epitopes TW10 and QW9, whereas HLA-B*57:03-and HLA-B*57:01-positive individuals also recognize the ISW9 and KF11 epitopes (13) . A response to KF11 p24-Gag is specifically detected in 73% and 59% of HIV-infected subjects expressing HLA-B*57:01 and -B*57:03, respectively (P ϭ 2 ϫ 10 Ϫ10 and 2 ϫ 10 Ϫ15 ) ( Fig. 1) and not in subjects expressing HLA-B*58:01. In a previous study, 9 HIV-specific epitopes, out of 16 that were seen to be recognized in subjects expressing HLA-B*57:03, were also recognized in subjects expressing HLA-B*58:01, and two additional epitopes were recognized by subjects expressing HLA-B*58:01 that were not also recognized by subjects expressing HLA-B*57:03 (13) . Thus, residues at positions 45, 46, and 97 of the HLA-B molecule affect immunogenicity of a number HIV-specific epitopes, including the KF11 Gag epitope, which is believed to contribute to immune control of HIV mediated by HLA-B*57:03 (10) .
The KF11 peptide can be presented by HLA-B*57:01, -B*57: 03, and -B*58:01 to KF11-specific CD8 ؉ T cells. A potential explanation for this failure of KF11 to be recognized by subjects expressing HLA-B*58:01 would be reduced binding affinity of KF11 for HLA-B*58:01 compared to HLA-B*57:01 and HLA-B*57:03. Similar HLA-B molecules with apparently identical peptide binding motifs can exhibit very different peptide binding affinities and stability off-rates to several HIV epitopes (11, 13) . To examine whether this could explain the differential KF11 epitope immunogenicity observed between HLA-B*57:01/03 and HLA-B*58:01, we tested the KF11 peptide binding affinity and binding half-life (stability) using previously published approaches based on refolding (8) or dissociation (9) of peptide, HLA, and ␤ 2 microglobulin (␤ 2 m) complexes, respectively, in a recombinant in vitro system. Unexpectedly KF11 has a very similar or even somewhat higher affinity, and a longer binding half-life, for HLA-B*58:01 than for HLA-B*57:01 ( Fig. 2A to D To explore this further, we pulsed B cells expressing HLA-B*57:01, -B*57:03, and -B*58:01 (Table 2) The KF11 epitope is not intracellularly processed by HLA-B*58:01-expressing target cells. To determine whether KF11 Gag presentation is influenced upstream of peptide HLA loading, we synchronously infected primary CD4 ϩ T cells derived from healthy individuals expressing either HLA-B*57:01, -B*57:03, -B*58:01, or irrelevant alleles (Table 2 ) with wild-type HIV NL4-3 to similar levels ( Fig. 3A) (12) . Endogenous processing and presentation of KF11 were then assessed by measuring activation (CD107a ϩ /MIP1␤ ϩ ) of cocultured HLA-B*57:01-restricted KF11-specific CD8 ϩ T cells, shown to recognize KF11 in the context of all three alleles (Fig. 2E ), for the duration of 6 h at 48 h postinfection (Fig. 3B ). From these data, it is clear that KF11 is well processed intracellularly and presented on the surfaces of HLA-B*57:01-and -B*57:03-positive but not HLA-B*58:01-positive cells. However, this was not a result of a general epitope processing failure by the HLA-B*58:01-positive target cells used here, illustrated by recognition of the IAW9-RT epitope following wild-type HIV NL4-3 infection (Fig. 3C ).
To confirm these findings, we repeated the experiment setup by infecting 6 different B-cell lines (Table 2 ) with vesicular stomatitis virus G (VSV-G)-pseudotype-like particles (12) ( Table  4 ) encoding all of the HIV proteins except envelope (VLP pCMV⌬R8.2) (24). Again, only target cells expressing HLA-B*57:01 and B*57:03 were able to endogenously process and present KF11 on the cell surface (Fig. 3D) . Thus, KF11 Gag presentation is abrogated by target cells expressing HLA-B*58:01, suggesting an upstream restriction prior to HLA loading and extracellular export. These data are consistent with the pattern of KF11 recognition summarized in Fig. 1 .
HLA-B*58:01 does not exclude endogenous KF11 processing in the presence of HLA-B*57. Having established that KF11 is satisfactorily presented by HLA-B*58:01 after peptide pulsing, but not following intracellular processing of HIV Gag after infection of target cells, we addressed the question of whether HLA-B*58:01 abrogates KF11 processing in vivo. To test this, we identified 4 chronic HIV infected individuals expressing both HLA-B*57:03 and -B*58:01, each of whom had been tested for recognition of the 18-mer WVWVIEEKAFSPEVIPMF or the 15-mer EEKAFSPEVI PMFTA, both containing the optimal KF11 epitope, and/or of the optimal KF11 itself. We observed strong KF11 Gag-specific CD8 ϩ T-cell responses ex vivo in all 4 individuals (Table 5) . Thus, the presence of HLA-B*58:01 does not abrogate the processing of the optimal KF11 epitope in infected cells if HLA-B*57:03 is also present. Taken together, these data show that, in HLA-B*58:01-positive individuals, the targeting of the protective KF11 Gag epitope is prevented by events upstream of peptide HLA loading during intracellular processing, which may ultimately impact HIV control (10, 13), resulting either from efficient killing of virus-infected targets (12) or through reduced viral replicative capacity from HLA-B*57-driven escape mutants within KF11-Gag (2, 3). This example also applies to HLA-B*57:02, which differs from HLA- (13) . In addition, we have observed multiple examples of other peptides which exhibited strong binding affinities for the relevant HLA molecule yet which were nonimmunogenic when peptide recognition was tested in a cohort of Ͼ1,000 HIV-infected study subjects (data not shown). This strongly suggests that the observation described here of KF11 binding to HLA-B*58:01, but lack of immunogenicity, is an example of a phenomenon that exists more widely. Potential explanations for this novel phenomenon include the following. First, it is possible that the HLA-B*58:01-KF11 complex has a lower binding affinity for the T-cell receptor (TCR) than do the HLA-B*57:01-KF11 and HLA-B*57:03-KF11 complexes. Second, we cannot rule out the possibility that the absence of KF11-specific CD8 ϩ T cell responses in HLA-B*58:01-positive individuals may result from a "gap" in the TCR repertoire. Third, lack of intracellular processing of KF11 after HIV infection suggests that HLA-B*58:01 interferes with processing events prior to peptide transport into the endoplasmic reticulum (ER), although this seems unlikely, as similar degradation patterns for Gag peptides have been observed for multiple donors with different HLA expression (14) . The most likely explanation may be abrogation of actual peptide loading within the peptide loading complex (PLC) in the ER, resulting in failure of the normal downstream egress from the ER, exit, and Golgi transport to the cell surface (21) .
The strong KF11-specific CD8 ϩ T-cell responses within individuals heterozygous for the presenting and nonpresenting alleles HLA-B*57:03 and -B*58:01, respectively, might indicate that the critical event occurs after proteosomal cleavage of the Gag-p24 protein, transporter associated with antigen processing (TAP) transport to the ER lumen, and ERAP-1 N-terminal trimming of the KF11 precursor peptide but prior to tapasin-ERp57 conjugate loading onto the HLA molecule. Peptide loading onto HLA class I molecules within the ER happens in the PLC, in which the exact regulation of HLA maturation and interaction with PLC proteins is still debated. The core of the PLC is composed of the TAP heterodimer in conjunction with the ERp57/tapasin conjugate, and multiple weak interactions within the PLC are necessary for optimal peptide loading, which is severely impaired for most HLA alleles after prevention of the interaction with tapasin (21) . Tapasin interacts only with alpha domain 2 of the HLA heavy chain, and in particular, residues 114 and 116 play an important role (20, 23) . Interestingly, while HLA-B*57:03 differs at these residues from HLA-B*57:01, HLA-B*57:01 and -B*58:01 do not, suggesting that tapasin dependence does not play a role here (21) . Furthermore, in this study we used wild-type primary CD4
ϩ T cells and wild-type B cell lines derived from multiple different human donors to study the intracellular processing of KF11 and therefore assume that these cells are equipped with fully functional tapasin along with a complete set of PLC proteins to ensure optimal regulation and processing of epitopes. Finally, another potential mechanism for the absence of KF11 epitope presentation on the surface of HLA-B*58:01 target cells may be that KF11 is outcompeted by other HLA-B*57/58:01-binding peptides, such as TW10, which has very strong binding affinity for both HLA-B*57:03 and -B*58:01 (IC 50 [K D ], 6 nM and 19 nM, respectively). However, while HLA-B*57:03-restricted KF11 responses dominate in chronic infection, HLA-B*58:01-restricted KF11 responses are not detectable, suggesting that outcompetition by high-avidity peptides such as TW10 is not the explanation.
This novel example shows how peptide presentation, immunogenicity, and ultimately clinical disease outcome can be governed at the level of intracellular processing, which is unrelated to optimal peptide binding affinity. Furthermore, it strongly implies the existence of yet-unknown events or mechanisms located within the PLC that influence peptide presentation by HLA class I alleles and raises the question of exactly how peptides are loaded onto HLA class I molecules by the PLC. Future studies are needed to determine how widespread this phenomenon is and to what extent it explains the observed difference in epitope repertoire of closely related HLA alleles. 
